Ami Organics Past Earnings Performance
Past criteria checks 1/6
Ami Organics has been growing earnings at an average annual rate of 11.1%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 21.3% per year. Ami Organics's return on equity is 7.1%, and it has net margins of 6%.
Key information
11.1%
Earnings growth rate
8.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 21.3% |
| Return on equity | 7.1% |
| Net Margin | 6.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ami Organics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 7,175 | 428 | 631 | 0 |
| 31 Dec 23 | 6,789 | 417 | 579 | 0 |
| 30 Sep 23 | 6,648 | 503 | 546 | 0 |
| 30 Jun 23 | 6,281 | 851 | 508 | 0 |
| 31 Mar 23 | 6,167 | 833 | 492 | 0 |
| 31 Dec 22 | 5,739 | 774 | 494 | 0 |
| 30 Sep 22 | 5,627 | 747 | 474 | 0 |
| 30 Jun 22 | 5,380 | 731 | 452 | 0 |
| 31 Mar 22 | 5,201 | 719 | 417 | 0 |
| 31 Dec 21 | 4,695 | 661 | 362 | 0 |
| 30 Sep 21 | 4,203 | 611 | 307 | 0 |
| 30 Jun 21 | 3,759 | 557 | 253 | 0 |
| 31 Mar 21 | 3,406 | 540 | 214 | 0 |
| 31 Mar 20 | 2,396 | 275 | 179 | 0 |
| 31 Mar 19 | 2,385 | 233 | 117 | 0 |
| 31 Mar 18 | 1,882 | 185 | 114 | 0 |
| 31 Mar 17 | 1,603 | 120 | 87 | 0 |
| 31 Mar 16 | 1,537 | 127 | 81 | 0 |
Quality Earnings: 543349 has a high level of non-cash earnings.
Growing Profit Margin: 543349's current net profit margins (6%) are lower than last year (13.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543349's earnings have grown by 11.1% per year over the past 5 years.
Accelerating Growth: 543349's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 543349 had negative earnings growth (-48.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.2%).
Return on Equity
High ROE: 543349's Return on Equity (7.1%) is considered low.